Search research articles
Contact Us
Filters
Showing results (121-130 of 133) with videos related to
Page
of 14
Sort By:
Future Oncology (London, England)
|
March 7, 2025
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, et al.
Intensive Care Medicine
|
May 4, 2026
Temporal trends and prognostic factors in critically ill adult patients with acute leukemia: an individual participant data meta-analysis
Dara Chean, Thibault Dupont, Joseph L Nates, et al.
Hemasphere
|
May 22, 2024
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
Fabio Efficace, Rena Buckstein, Gregory A Abel, et al.
American Journal of Hematology
|
July 5, 2017
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems
Rena Buckstein, Enrico Balleari, Richard Wells, et al.
The Lancet. Haematology
|
December 22, 2023
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, et al.
Blood
|
February 1, 2023
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
Amer M Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, et al.
The New England Journal of Medicine
|
January 9, 2020
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux, Uwe Platzbecker, Ghulam J Mufti, et al.
Blood Reviews
|
March 18, 2023
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1<sup>st</sup> International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, et al.
Leukemia
|
October 20, 2022
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes
Amer M Zeidan, Jan Philipp Bewersdorf, Rena Buckstein, et al.
Blood Reviews
|
September 13, 2023
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 133) with videos related to
Sort By:
Page
of 14
Future Oncology (London, England)
|
March 7, 2025
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, et al.
Intensive Care Medicine
|
May 4, 2026
Temporal trends and prognostic factors in critically ill adult patients with acute leukemia: an individual participant data meta-analysis
Dara Chean, Thibault Dupont, Joseph L Nates, et al.
Hemasphere
|
May 22, 2024
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
Fabio Efficace, Rena Buckstein, Gregory A Abel, et al.
American Journal of Hematology
|
July 5, 2017
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems
Rena Buckstein, Enrico Balleari, Richard Wells, et al.
The Lancet. Haematology
|
December 22, 2023
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, et al.
Blood
|
February 1, 2023
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
Amer M Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, et al.
The New England Journal of Medicine
|
January 9, 2020
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux, Uwe Platzbecker, Ghulam J Mufti, et al.
Blood Reviews
|
March 18, 2023
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1<sup>st</sup> International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, et al.
Leukemia
|
October 20, 2022
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes
Amer M Zeidan, Jan Philipp Bewersdorf, Rena Buckstein, et al.
Blood Reviews
|
September 13, 2023
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, et al.
Page
of 14